```markdown
---
application_number: NDA 210136
applicant: Braeburn Inc.
drug_name: BRIXADI
active_ingredient: buprenorphine
dosage_form: extended-release injection for subcutaneous use
application_type: 505(b)(2)
original_submission_date: 2017-07-19
complete_response_date: 2021-06-15
action_letter_date: 2020-12-01
contact_person:
  name: Susan Franks, MS
  title: Senior Vice President of Regulatory Affairs
  address: 450 Plymouth Road, Suite 400, Plymouth Meeting, PA 19462
fda_contact:
  name: Rita Joshi
  title: Regulatory Project Manager
  email: rita.joshi@fda.hhs.gov
responsible_official:
  name: Celia Winchell, MD
  title: Associate Director for Addiction Medicine, Division of Anesthesiology, Addiction Medicine, and Pain Medicine, Office of Neuroscience, Center for Drug Evaluation and Research
reference_id: 4905207
---

## Critical Data

- **Application Number:** NDA 210136  
- **Applicant:** Braeburn Inc.  
- **Drug Name:** BRIXADI  
- **Active Ingredient:** Buprenorphine  
- **Dosage Form:** Extended-release injection for subcutaneous use  
- **Application Type:** 505(b)(2)  
- **Original Submission Date:** July 19, 2017  
- **Complete Response Submitted:** June 15, 2021  
- **Prior Action Letter Date:** December 1, 2020  
- **Contact Person:** Susan Franks, MS — Senior VP of Regulatory Affairs  
- **FDA Contact:** Rita Joshi — Regulatory Project Manager (rita.joshi@fda.hhs.gov)  
- **Responsible FDA Official:** Celia Winchell, MD  
- **Reference ID:** 4905207  

---

# NDA 210136 — COMPLETE RESPONSE LETTER

Braeburn Inc.  
450 Plymouth Road, Suite 400  
Plymouth Meeting, PA 19462  

Attention: Susan Franks, MS  
Senior Vice President of Regulatory Affairs  

---

## INTRODUCTION

Please refer to your new drug application (NDA) dated and received July 19, 2017, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for **BRIXADI** (buprenorphine) extended-release injection for subcutaneous use.

We acknowledge receipt of your amendment dated June 15, 2021, which constituted a complete response to our December 1, 2020, action letter.

We have completed our review of this application as amended and have determined that we cannot approve this application in its present form. Our reasons for this action are described below.

---

## FACILITY INSPECTIONS

During a recent inspection for this application of:

- Pharmaceutics International (FEI 3006503102), manufacturing and testing facility, Cockeysville, MD  
- Pharmaceutics International (FEI 1000513101), warehouse and testing facility, Hunt Valley, MD

...our field investigator conveyed deficiencies to the representatives of each facility. Satisfactory resolution of these deficiencies is required before this application may be approved.

---

## PRESCRIBING INFORMATION

Submit draft labeling that is responsive to our communication dated December 15, 2021.

- Before resubmitting, use the SRPI checklist to correct formatting errors aligned with regulations and guidance.
- Submit updated content of labeling (21 CFR 314.50(l)(1)(i)) in SPL format.
- Provide both:
  - A marked-up copy (highlighted/annotated) showing changes  
  - A clean Word version

Your proposed PI must conform to:

- 21 CFR 201.56(a) and (d)
- 21 CFR 201.57

### Refer to the Following Resources:

- Final Rule: Physician Labeling Rule  
- Final Rule: Pregnancy and Lactation Labeling Rule  
- Regulations and related guidance documents  
- Sample format tool for Highlights and Contents  
- Selected Requirements for Prescribing Information (SRPI)  
- FDA’s Established Pharmacologic Class (EPC) text phrases  
- Additional resources for the PI, patient labeling, and packaging

---

## PROPRIETARY NAME

Refer to correspondence dated September 7, 2021. The name **BRIXADI** was found acceptable, pending application approval. Please resubmit the proposed proprietary name with the response to application deficiencies.

---

## RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

We acknowledge submission of your proposed modified REMS on:

- July 6, 2021 — Medication Guide, elements to assure safe use, implementation system, and assessment timetable  
- October 22, 2021 (amended December 1, 2021) — REMS Supporting Document and Assessment Plan

We will make a final decision on the proposed modified REMS after receiving a complete response to this action letter.

---

## SAFETY UPDATE

When responding to the deficiencies, include a safety update per 21 CFR 314.50(d)(5)(vi)(b), which should include:

1. Details of any significant changes/findings in the safety profile  
2. New safety data from:
   - Proposed indication trials  
   - Tabulations combining new and original application data  
   - Tables comparing AE frequencies between new and original datasets  
   - Separate AE tables for other indications  
3. Retabulation of premature trial discontinuation causes, and any new emerging trends  
4. Case report forms and narrative summaries for:
   - Trial deaths  
   - Adverse event-related discontinuations  
   - Serious adverse events  
5. Information on changes in incidence of common but less serious AEs  
6. Updated exposure data (subject counts, person-time)  
7. Summary of worldwide safety experience and updated usage estimates in other countries  
8. English translations of current approved foreign labeling not otherwise submitted previously  

---

## POSTMARKETING REQUIREMENTS UNDER 505(o)(3)

If NDA 210136 is approved, postmarketing studies will be required to assess:

- Precipitated withdrawal risks from initial BRIXADI doses (24–32 mg weekly; 64–96 mg monthly)  
- Unknown risks associated with elemental impurities or leachables from container closure components

### Required Studies:

1. **Weekly Dosing Safety Trial (24–32 mg without titration)**  
   - Objective: Identify accelerated dose-initiation regimen and precipitated withdrawal risk  
   - Must define criteria for withdrawal and dose inadequacy

2. **Monthly Dosing Safety Trial (64–96 mg without prior treatment)**  
   - Objective: Same as above tailored to monthly dosing regimen  
   - Must define criteria as above

---

## OTHER

You are required to take one of the permissible actions under 21 CFR 314.110 within one year of this letter. Otherwise, your application may be considered withdrawn under 21 CFR 314.65.

- A resubmission:
  - Must address all deficiencies  
  - Must be clearly marked with **"RESUBMISSION"** in bold, large font in the cover letter  
  - Must state explicitly that it constitutes a complete response  
  - A partial response will not initiate a new review cycle

You may request a meeting or teleconference to clarify necessary steps prior to approval. Follow guidance in FDA's draft guidance on formal meetings for PDUFA products.

This drug product may not be legally marketed until approved in writing by FDA.

---

## CONTACT

If you have any questions, contact:

**Rita Joshi**  
Regulatory Project Manager  
rita.joshi@fda.hhs.gov  

---

Sincerely,  
**Celia Winchell, MD**  
Associate Director for Addiction Medicine  
Division of Anesthesiology, Addiction Medicine, and Pain Medicine  
Office of Neuroscience  
Center for Drug Evaluation and Research  

Reference ID: 4905207
```